SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced it has expanded its global license agreement with CURx Pharmaceuticals, Inc. to also include the development and commercialization of Ligand’s Captisol-enabled™ Lamotrigine program. Under the terms of the expanded license, Ligand will be eligible to receive $22 million in potential milestone payments, revenue from the sales of Captisol, and tiered royalties on future net sales in the range of 4% to 7% for Captisol-enabled™ Lamotrigine. CURx will be responsible for all costs related to the program.
“This is Ligand’s second program licensed to CURx and is another example of the importance of our Captisol® formulation technology to enable new and highly differentiated programs. We are pleased that our relationship with CURx has expanded with the licensing of Captisol-enabled™ Lamotrigine, a product candidate targeting hospital-based seizures,” commented John Higgins, President and Chief Executive Officer of Ligand. “Captisol-enabled™ Lamotrigine adds to our growing pipeline of over 100 partnerships.”
Help employers find you! Check out all the jobs and post your resume.
